Læknaneminn - 01.04.1997, Qupperneq 137

The drug-AIDS hypothesis *
with stable nonprogressing HIV type 1 infection. Aids Research and
Human Retroviruses 1996; 12: 585-592.
264. Garbulgia AR, Salvi R, Dicaro A, Cappiello G, et al. In vitro acti-
vation of HIV RNA expression in peripheral blood lymphocytes as
a marker to predict the stability of non-progressor status in long-
term survivors. AIDS 1996; 10: 17-21.
265. Baltimore D. Lessons from people with nonprogressive HIV infec-
tion (editorial; comment). N Engl J Med 1995; 332: 259-260.
266. Hand TH. Antiviral Drugs versus Long-Term Survival; Why antivi-
ral drugs cannot resolve AIDS. Reappraising AIDS 1996; 4: 1-4.
267. Maddox J. Rage and confusion hide role of HIV. Nature 1992;
357: 188-189.
268. Simmons T. Living on the edge. The Advocate 1995; December:
25-28, December 26.
269. Merson MH. Slowing the spread of HIV: Agenda for the 1990s.
Science 1993; 260: 1266-1268.
270. World Health Organization. The current Global Situation of the
HIV/AIDS Pandemic. 1995;
271. Strathdee SA, Craib KJP, Hogg RS, M. OS, Montaner J, Schechter
MT. Long-term non-progression in HIV infection. Lancet 1995;
346: 1372.
272. Cocchi F, DeVico A, Grazino-Demo A, Arya SK, Gallo RC, Lusso
P. Identification of Rabntes, Mip-la, and Mip-lb as the major HIV-
suppressive factors produced by CD8+ T cells. Science 1995; 270:
1811-1815.
273. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein
W, Jr. Patterns ofT lymphocyte changes with human immunodefi-
ciency virus infection: from seroconversion to the development of
AIDS. JAIDS 1989; 2: 63-69.
274. Lang W, Anderson RE, Perkins H, Grant RM, Lyman D,
Winkelstein W, Royce R, Levy JA. Clinical, Immunologic, and
Serologic Findings in Men at Risk for Acquired Immunodeficiency
Syndrome. JAMA 1987; 257: 326-330.
275. Ellison BJ, Downey AB, Duesberg PH. HIV as a surrogate marker
for drug-use: a re-analysis of the San Francisco Men’s Health Study.
Genetica 1995; 95: 165-171.
276. Marion SA, Schechter MT, Weaver MS, McLeod WA, Boyko WJ,
Willoughby B, Douglas B, Craib KJP, O’Shaughnessy M. Evidence
that prior immune dysfunction predisposes to human immunodefi-
ciency virus infection in homosexual men. JAIDS 1989; 2: 178-
186.
277. Archibald CP, Schechter MT, Le TN, Craib KJP, Montaner JSG,
O’Shaughnessy MV. Evidence for a sexually transmitted cofactor for
AIDS-related Kaposi’s sarcoma in a cohort of homosexual men.
Epidemiology 1992; 3: 203-209.
278. Kaslow RA, Phair JP, Freidman HB, Lyter RE, Solomon RE, Dudley
J, Polk F, Blackwelder W. Infection with the Human
Immunodeficiency Virus: clinical manifestations and their relation-
ship to immunodeficiency. Ann Intern Med 1987; 107: 474-480.
279. Ostrow DG, Van Raden MJ, Fox R, Kingsley LA, Dudley J, Kaslow
RA, the Multicenter AIDS Cohort Study (MACS). Recreational
drug use and sexual behavior change in a cohort of homosexual men.
AIDS 1990; 4: 759-765.
280. Phair J, Jacobson L, Detels R, Rinaldo C, Saah A, Schrager L,
Munoz A. Acquired immune deficiency syndrome occuring within
5 years of infection with human immunodeficiency virus type-1:
The multicenter AIDS cohort study. J Acquired Immune
Deficiency Syndromes 1992; 5: 490-496.
281. Parke D. Key factor. The Sunday Times (London) 1993: letter,
Dec. 19.
282. Seidman SN, Rieder RO. A Review of Sexual Behaviour in the
United States. The American Journal ofPsychiatry 1994; 151: 330-
341.
283. Des Jarlais DC, Friedman SR, Marmor M, Mildvan D, Yancovitz S,
Sotheran JL, Wenston J, Beatrice S. CD4 Lymphocytopenia among
injecting drug users in New York City. J Acquir Immune Defic
Syndr 1993; 6: 820-822.
284. Nicolosi A, Musico M, Saracco A, Molinari S, Ziliani N, Lazzarin A.
Incidence and risk factors of HIV infection: A prospective study of
seronegative drug users from Milan and Northern Italy, 1987-1989.
Epidemiology 1990; 1: 453-459.
285. Moore PS, Chang Y. Detection of Herpesvirus-like DNA Sequences
in Kaposi’s Sarcoma in Patients With and Those Without HIV
Infection. N Engl J Med 1995; 332: 1181-1185.
286. Weiss SH, Weston Klein C, Mayur RK, Besra J, Denny TN.
Idiopathic CD4+ T-lymphocytopenia. Lancet 1992; 340: 608-609.
287. Gottlieb MS, Schanker HM, Fan PT, Saxon A, Weisman JD,
Pozalski J. Pneumocystis pneumonia—Los Angeles. Morbidity and
Mortality Weekly Reports 1981; 30: 250-252.
288. Haverkos HW. Kaposi’s sarcoma and nitrite inhalants, in
Psychological, Neuropsychiatric and Substance Abuse Aspects of
AIDS, T. P. Bridge, H. Heather and M. Johnson (eds.) Raven Press,
NewYork, 1988; 165-172.
289. van Griensven GJP, Vroome EMM, de Wolf H, Goudsmit J, Roos
M, Coutinho RA. Risk factors for progression of human immun-
odeficiency virus (HIV) infection among seroconverted and seropos-
itive homosexual men. Am J Epidemiol 1990; 132: 203-210.
290. Graham NMH, Zeger SL, Park LP, Phair JP, Detels R, Vermund SH,
Ho M, Saah AJ, Multicenter AIDS Cohort Study. Effect of zidovu-
dine and Pneumocystis carinii pneumonia prophylaxis on progres-
sion ofHIV-1 infection to AIDS. Lancet 1991; 338: 265-269.
291. Seage GR, Mayer KH, Horsburgh CR, Holmberg SD, Moon MW,
Lamb GA. The relation between nitrite inhalants, unprotected
receptive anal intercourse, and the risk of human immunodeficiency
virus infection. J Am Epidemiol 1992; 135: 1-11.
292. Winkelstein W, Jr., Lyman DH, Padian N, Grant R, Samuel M,
Wiley JA, Anderson RE, Lang W, Riggs J, Levy JA. Sexual practices
and risk of infection by the human immunodeficiency virus: The
San Francisco men’s health study. JAMA 1987; 257: 321-325.
293. Lemp GF, Payne SF, Rutherford GW, Hessol NA, Winkelstein W,
Jr., Wiley JA, Moss AR, Chaisson RE, Chen RT, Feigal DW,
Thomas PA, Werdegar D. Projections of AIDS morbidity and mor-
tality in San Francisco. J Am Med Assoc 1990; 263: 1497-1501.
294. Mathur-Wagh U, Mildvan D, Senie RT. Follow-up of 4 1/2 years
on homosexual men with generalized lymphadenopathy. NEJM
1985; 313: 1542-1543.
295. San Francisco Department of Public Health, Lesbian & Gay
Substance Abuse Planning Group. Gay Men, Lesbians and their
Alcohol and Other Drug Use: A Review of the Literature. 1991
September;
296. Selik RM, Starcher ET, Curran JW. Opportunistic diseases report-
ed in AIDS patients: frequencies, associations, and trends. AIDS
1987; 1: 175-182.
297. Friedman-Kien AE, Saltzman BR, Cao Y, Nestor MS, Mirabile M,
Li JJ, Peterman TA. Kaposi’s sarcoma in HlV-negative homosexual
men. Lancet 1990; 335: 168-169.
298. Safai B, Peralta H, Menzies K, Tizon H, Roy P, Flomberg N,
Wolinsky S. Kaposi’s sarcoma among HlV-negative high risk popu-
lation. VII International Conference on AIDS. 1991;
299. Anonymous. Patient accuses Kaiser. Oakland Tribune 1992;
December 1.
300. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. Is a posi-
tive Western blot proof of HIV infection? Biotechnology 1993; 11:
696-707.
301. Johnson, C., Zenger’s magazine, California. Sept. 1996. Factors
known to cause false-positie HIV antibody test results. Continuum
(London) 1996; 4: 5,
302. Cohen J. Is a new virus the cause of KS? Science 1994; 266: 1803-
1804.
303. Ascher MS, Sheppard HW, Winkelstein Jr. W. AIDS-associated
Kaposi’s sarcoma (letter). Science 1995; 267: 1080.
304. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Adderman
MH, Klein RS, Freidland SH. Increased risk of bacterial pneumo-
nia in HlV-infected intravenous drug users without AIDS. AIDS
1988; 2: 267-272.
305. Braun MM, Truman BI, Maguire B, Di Ferdinando GT, Jr.,
Wormser G, Broaddus R, Morse DL. Increasing incidence of tuber-
culosis in a prison inmate population, associated with HlV-infec-
tion. J Am Med Assoc 1989; 261: 393-397.
306. Centers for Disease Control. Revision of the CDC surveillance case
definition for acquired immunodeficiency syndrome. JAMA 1987;
258: 1143-1154.
307. Annell A, Fugelstad A, Ágren G. FlIV-prevalence and mortality in
relation to type of drug abuse among drug addicts in Stockholm
LÆKNANEMINN
135 1- tbl. 1997, 50. árg.